United Therapeutics Corporation has announced a significant increase in its third-quarter revenues, reflecting strong growth and operational efficiency. The company reported total revenues of $832.5 million for the quarter ending September 30, 2026, marking a 4% increase from $799.5 million in the same period last year. This performance highlights the company’s successful strategies and its commitment to expanding its therapeutic portfolio.

Martine Rothblatt, Ph.D., Chairperson and CEO of United Therapeutics, emphasized the company’s trajectory, stating, “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.” This sentiment reflects the company’s focus on innovation and its potential to impact the pharmaceutical landscape significantly.

The company operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. This sector is characterized by intense competition and a constant need for innovation, particularly as companies strive to meet the evolving needs of patients. The strong performance reported by United Therapeutics may influence competitors to enhance their own product offerings and strategies.

Michael Benkowitz, President and COO, also commented on the results, noting, “Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.” He highlighted the company’s robust foundation and the significant opportunities in cardiopulmonary and respiratory medicine.

The filing, dated November 4, 2026, includes a press release detailing these financial results, attached as Exhibit 99.1. The information provided in this filing indicates that United Therapeutics is not only maintaining its current market position but is also poised for future growth.

Looking ahead, the company’s focus on expanding its therapeutic offerings and enhancing patient access is likely to continue driving its growth. The filing does not specify what the next steps will be, but the positive financial results suggest that United Therapeutics will pursue further innovations and potentially explore new market opportunities.